Evidence map›Paper›PMID 36606344›Full record

ArticleJournal of biomedical materials research. Part A2023

Interval delivery of 5HT

Mehjabeen Hossain, Suresh P Sulochana, Katie E Heath, Saif Mohammad Ishraq Bari, Parker Brewster, Jared Barnes, Azim Munivar, Glenn M Walker, David A Puleo, Thomas A Werfel

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of biomedical materials research. Part A, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.6field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 2 citations in OpenAlex.

  1. Article
  2. Rise of implantable drugs: A chronicle of breakthroughs in drug delivery systems.Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society · 2024
    Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 1 country.

Mehjabeen HossainDepartment of BioMolecular Sciences, University of Mississippi, University, Mississippi, USA.
Suresh P SulochanaCenter of Biomedical Research Excellence in Natural Products Neuroscience, University of Mississippi, University, Mississippi, USA.
Katie E HeathCenter of Biomedical Research Excellence in Natural Products Neuroscience, University of Mississippi, University, Mississippi, USA.
Saif Mohammad Ishraq BariDepartment of Biomedical Engineering, University of Mississippi, University, Mississippi, USA.
Parker BrewsterDepartment of Biomedical Engineering, University of Mississippi, University, Mississippi, USA.
Jared BarnesDepartment of Biomedical Engineering, University of Mississippi, University, Mississippi, USA.
Azim MunivarResearch and Development, BioHaven Pharmaceuticals, Inc, New Haven, Connecticut, USA.
Glenn M WalkerDepartment of Biomedical Engineering, University of Mississippi, University, Mississippi, USA.
David A PuleoOffice of the Provost, The University of Alabama in Huntsville, Huntsville, Alabama, USA.
Thomas A WerfelDepartment of BioMolecular Sciences, University of Mississippi, University, Mississippi, USA.
University of Mississippi · USBiohaven Pharmaceuticals (United States) · USUniversity of Alabama in Huntsville · USUniversity of Mississippi Medical Center · US

Funding

Pilot Project ProgramP30GM122733 · NIGMS · UNIVERSITY OF MISSISSIPPI · PI MAJUMDAR, SOUMYAJIT · 2018 to 2022
$5.3M
Biodegradable microfuses to enable the safe and compliant long-term interval dosing of 5HT2A agonistsR21EB031454 · NIBIB · UNIVERSITY OF MISSISSIPPI · PI WALKER, GLENN MADISON, WERFEL, THOMAS A · 2021 to 2022
$402k
NIBIB NIH HHS R21 EB031454NIGMS NIH HHS P30 GM122733
6 · The paper itself

Abstract

There is an urgent unmet medical need to develop therapeutic options for the ~50% of depression patients suffering from treatment-resistant depression, which is difficult to treat with existing psycho- and pharmaco-therapeutic options. Classical psychedelics, such as the 5HT

Indexed as

HallucinogensHumansPharmaceutical PreparationsPolymersTissue DistributionHallucinogensPharmaceutical PreparationsPolymers5HT2A agonistinterval drug deliverymicrodosingpolymeric filmspsychedelics

Identifiers

PMID36606344
PMCPMC10101876
OpenAlexW4313647233

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.